Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-07-21
Tempus AI, Inc.
Provides genomic testing, clinical workflow software, and governed de-identified data and AI services for providers, researchers, and biopharma customers.
ai biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A healthcare data flywheel nearing proof mode
This is a real diagnostics-and-data platform, not just an AI wrapper. The five-year upside depends on converting assay scale into better reimbursement, recurring data demand, and trusted workflow monetization before valuation patience runs out.

Analysis

Thesis
Tempus can outgrow a normal diagnostics company because each added clinical test can feed better reimbursement, more valuable governed data, and higher-margin workflow software; if management converts that loop into recurring paid usage while tightening cash burn, equity value can still compound materially over five years without needing a pure software rerating.
Last Economy Alignment
Cheaper AI makes Tempus' governed clinical data, regulated assays, and embedded workflows more useful rather than obsolete. Strong switching costs and low agent bypass risk help, but value capture still must move beyond test economics.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
The upside case is mostly operational, not narrative. Core oncology and hereditary testing can keep growing, FDA-backed reimbursement changes can raise price per case, and Data & Applications can become a larger share of mix. That mix shift deserves some rerating, but Tempus still looks like a regulated healthcare platform with lab exposure, not a pure software asset. That supports strong compounding, but not moonshot underwriting.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is economic conversion, not product existence. Tempus already has real diagnostics, data, and workflow assets; the question is whether reimbursement gains, data monetization, and applications growth arrive fast enough to offset capital needs and keep the business from being valued as a premium lab rather than a trusted healthcare software-and-data layer.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.65
They control hard-to-copy cancer data and sit inside real clinical workflows, so stronger AI makes their system more useful each time another patient and doctor use it. The risk is that reimbursement, privacy rules, or bigger software owners capture the value before Tempus does.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$66.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case